CDC42EP2

Across TCGA pan-cancer cohorts, CDC42EP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDC42EP2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDC42EP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDC42EP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where CDC42EP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.817	0.926	.016	7	view →
HNSC	DFS	Median	All	0.849	0.355	.034	6	view →
LUAD	DFS	Quartile	All	1.000	0.386	.001	5	view →
LSCC	OS	Median	II,III,IV	0.904	1.000	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDC42EP2–PDAC (OS)

Open the PDAC breakdown →